Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.73 |
| ▸ | KIT | P10721 | 1/20 | 0.68 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 17/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13166644 | 0.89 | MET (0.72) | METKITPDGFRAKDR | |
| SCHEMBL13166667 | 0.88 | MET (0.81) | METKDR | |
| SCHEMBL3573526 | 0.86 | MET (0.81) | METKITPDGFRAKDR | |
| SCHEMBL14206046 | 0.86 | MET (0.66) | METKITPDGFRAKDR | |
| SCHEMBL3559644 | 0.85 | MET (0.68) | METKITPDGFRAKDR | |
| SCHEMBL3572769 | 0.85 | MET (0.63) | METKITPDGFRAKDR | |
| SCHEMBL3564902 | 0.85 | MET (0.62) | METKITPDGFRAKDR | |
| SCHEMBL3559381 | 0.85 | MET (0.67) | METKITPDGFRAKDR | |
| SCHEMBL3570669 | 0.84 | MET (0.81) | METKITPDGFRAKDR | |
| SCHEMBL3563117 | 0.84 | MET (1.00) | METKITPDGFRAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | MET 1062/4885KIT 492/4885PDGFRA 357/4885 |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | HGF, MET, FLT1 | MET 2/4885KIT 124/4885PDGFRA 13/4885 |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | HGF, MET, FLT1 | MET 2/4885KIT 132/4885PDGFRA 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.